Aim To Cut Drug Prices By Asian Governments May Backfire, Discourage Investment – IMS
This article was originally published in PharmAsia News
Executive Summary
Efforts by Asian governments to reduce drug prices may have little impact on healthcare provision and may in fact backfire by driving some drugs out of the market.
You may also be interested in...
Coalition Blames Slow Judicial Process and Parallel Drug Importation Program For Fake Drugs In Philippines
SHANGHAI - The Coalition Against Fake Medicines, a group of multisectoral representatives in the healthcare industry, including pharmacists, retailers, and generics companies in the Philippines, recently called the country's slow judicial process a major factor in the rise of fake medicines, and said the government's parallel drug importation program under the Cheap Medicine Act partly helps counterfeits enter the country
Philippine Drug Price Controls Pinch Brands And Generics
SHANGHAI - State-mandated price cuts in the Philippines on branded drugs are putting some generics makers in a tight spot. The government price controls, which began in August 2009, have spread swiftly, and the caps affecting commonly prescribed drugs are now pressuring their generic competitors
Philippines Plans A New Round Of Drug Price Cuts For Branded Products
SHANGHAI - The Philippines' Department of Health is mapping out plans for yet another round of drug price cuts following those imposed in mid-2009 and in early 2010